- Home
- TCRX vs CNTX Comparison
TCRX vs CNTX Comparison
Compare TCRX & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | CNTX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 47.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TCRX | CNTX |
|---|---|---|
| Price | $0.75 | $0.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $7.00 | $6.60 |
| AVG Volume (30 Days) | 311.4K | ★ 2.1M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.28 | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.72 | $0.40 |
| 52 Week High | $2.57 | $3.62 |
Technical Indicators
Market Signals| Indicator | TCRX | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 32.72 |
| Support Level | $0.73 | N/A |
| Resistance Level | $0.82 | $0.55 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 9.48 | 17.07 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.